SCHEMBL21116679

SCHEMBL21116679

C=C/C(=C\C(=C/C(=C)C(=O)O)C(=O)O)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.35
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19003733 0.95 LMNA (0.38) LMNAALOX15HSD17B10
SCHEMBL3189966 0.95 LMNA (0.38) LMNAALOX15HSD17B10
SCHEMBL22193118 0.74 CYP2C9 (0.34)
SCHEMBL345324 0.74 LMNA (0.50) LMNAALOX15HSD17B10
SCHEMBL1661967 0.74 LMNA (0.50) LMNAALOX15HSD17B10
SCHEMBL316986 0.74 LMNA (0.50) LMNAALOX15HSD17B10
SCHEMBL21191374 0.73 LMNA (0.36) LMNA
SCHEMBL16625654 0.73 LMNA (0.36) LMNAALOX15HSD17B10
SCHEMBL22193124 0.73
SCHEMBL28414100 0.72 LMNA (0.40) LMNAALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078219-B2 Method for producing coordinatively unsaturated metal-organic framework and coordinatively unsaturated metal-organic framework TOYOTA JIDOSHA KABUSHIKI KAISHA 2021-08-03 US disclosed
US-11008347-B2 Metal-organic framework and method of producing the same TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2021-05-18 US disclosed
US-10702851-B2 Metal-organic framework and method of manufacturing the same TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2020-07-07 US disclosed
US-20190194232-A1 METAL-ORGANIC FRAMEWORK AND METHOD OF PRODUCING THE SAME TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10702851-B2 Metal-organic framework and method of manufacturing the same TRIM4, TRIM24, PICALM LMNA 3841/4885ALOX15 2360/4885HSD17B10 2059/4885
US-11078219-B2 Method for producing coordinatively unsaturated metal-organic framework and coordinatively unsaturated metal-organic framework TRPM8, F8, SLC16A8 LMNA 2331/4885ALOX15 533/4885HSD17B10 4084/4885
US-20190194232-A1 METAL-ORGANIC FRAMEWORK AND METHOD OF PRODUCING THE SAME TRIM4, MDM4, TRIM59 LMNA 3781/4885ALOX15 3412/4885HSD17B10 3906/4885
US-11008347-B2 Metal-organic framework and method of producing the same TRIM4, MDM4, TRIM59 LMNA 3781/4885ALOX15 3412/4885HSD17B10 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.